Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces a share repurchase program. Under the program, the company will repurchase up to 350,000 shares, representing 2.23% of its issued share capital (excluding treasury stock), for a total purchase price of ¥1,000 million. The purpose of the program is to improve capital efficiency and enhance shareholder returns.

The plan will expire on June 28, 2024. As of March 31, 2024, the company has 15,690,407 issued shares (excluding treasury stock) and 8,033 treasury shares.